Accredited Educational Activities

Hope on the Horizon: Emerging Treatment Options for Patients with Retinopathy of Prematurity

This enduring program about retinopathy of prematurity (ROP) targets key concepts about pathophysiology and the role of vascular endothelial growth factor (VEGF), screening, and management for this potentially visually blinding disorder of premature infants. Learn essential elements for recognizing infants at risk, timelines to ROP development, current advances in treatment approaches and critical examination timeframes to help prevent progression as well as complications of advanced disease.

On February 8, 2023, aflibercept received FDA-approval for the pharmacologic treatment of pre-term infants with retinopathy of prematurity (ROP). Approval was based on the FIREFLEYE and BUTTERFLEYE studies, where 80% of treated infants across both studies achieved an absence of active ROP as well as unfavorable structural outcomes at 52 weeks of age.